Evidence map›Paper›PMID 38999983›Full record

ArticleInternational journal of molecular sciences2024

Development of a Radiolabeled Cyclin-Dependent Kinases 4 and 6 (CDK4/6) Inhibitor for Brain and Cancer PET Imaging.

Chun-Han Huang, Palwasha Khan, Sulan Xu, Jules Cohen, Georgios V Georgakis, Nashaat Turkman

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. New Radiopharmaceutical Tracers in Breast Cancer Diagnosis and Therapy.Anti-cancer agents in medicinal chemistry · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Chun-Han HuangStony Brook Cancer Center, Stony Brook, Long Island, NY 11794, USA.
Palwasha KhanStony Brook Cancer Center, Stony Brook, Long Island, NY 11794, USA.
Sulan XuStony Brook Cancer Center, Stony Brook, Long Island, NY 11794, USA.
Jules CohenStony Brook Cancer Center, Stony Brook, Long Island, NY 11794, USA.
Georgios V GeorgakisStony Brook Cancer Center, Stony Brook, Long Island, NY 11794, USA.
Nashaat TurkmanStony Brook Cancer Center, Stony Brook, Long Island, NY 11794, USA.ORCID 0000-0002-7943-6637

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The synthesis, biochemical evaluation and radiosynthesis of a cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitor and radioligand was performed. NT431, a newly synthesized 4-fluorobenzyl-abemaciclib, exhibited high potency to CDK4/6 and against four cancer cell lines with IC

Indexed as

AminopyridinesBenzimidazolesBrain NeoplasmsCyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6Positron-Emission TomographyProtein Kinase InhibitorsAnimalsBrainCell Line, TumorFemaleFluorine RadioisotopesHumansMiceRadiopharmaceuticalsabemaciclibAminopyridinesBenzimidazolesCDK4 protein, humanCDK6 protein, humanCyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6Fluorine RadioisotopesProtein Kinase InhibitorsRadiopharmaceuticalsabemaciclibBBBCDK4/6CNSPET

Identifiers

PMID38999983
PMCPMC11241330

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.